Pathogen scientist collaborating on vaccine that could prevent and treat COVID-19
PKU-led team found effective SARS-CoV-2 neutralizing antibodies
Sorrento’s COVID-19 Antidote Could be a Game Changer, Says Analyst
Promising pre-clinical results for USask VIDO-InterVac COVID-19 vaccine
Eli Lilly, Junshi Biosciences To Start Human Testing Of Covid-19 Antibodies By Q2
Regeneron to buy back $5 billion stake held by Sanofi
Fate Therapeutics (FATE) Cleared By FDA of IND Application for FT538
Novavax is latest biotech to begin coronavirus vaccine trial
Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July
Rebuilding Trust in Coronaworld
New technology can detect anti-virus antibody in 20 minutes
Airway Therapeutics, Celonic Group partner to produce AT-100 as candidate for coronavirus
Can Moderna Win the COVID-19 Vaccine Race?
BIDMC-developed vaccines protect against COVID-19 in non-human primates, study finds
Prellis Bio’s Externalized Human Immune System rapidly generates 300 SARS-CoV2 antibodies
Moderna stock volatile amid work on coronavirus vaccine
X-ray experiments zero in on COVID-19 antibodies
Moderna Prices $1.3B Equity Offering at $76/Share
Sorrento (SRNE) Stock Is up 140% in Two Days. How Much Higher Can It Go?
Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data
Covid-19 roundup: Kate Bingham to lead UK taskforce; Federal judge to Shkreli: You’re not going to save the world, stay in prison
Scientists collaborate to create new physics-based technology for COVID-19 detection
Applied DNA Sciences Tackles COVID-19 on Three Fronts; Analyst Says 'Buy'
Skilled partners in the conduct of HIV prevention trials join COVID-19 response
COVID-19: Science and Economics
Moderna’s COVID-19 Vaccine Candidate Progressing at 'Warp Speed,' Says Top Analyst
Alberta researchers, Tonix Pharmaceuticals race to develop candidate vaccines for COVID-19
Merck CPO Julie Gerberding On The Deadliness Of Covid-19
Epic CEO Judy Faulkner on developing new therapies for COVID-19
Moderna CEO Stephane Bancel & Regeneron CEO Leonard Schleifer on a Coronavirus vaccine